ArriVent BioPharma
AVBP
139 hedge funds and large institutions have $969M invested in ArriVent BioPharma in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 17 closing their positions.
245% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $3.56M
112% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 17
104% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 28
20% more capital invested
Capital invested by funds: $810M → $969M (+$159M)
15% more funds holding
Funds holding: 121 → 139 (+18)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.92% less ownership
Funds ownership: 97.14% → 95.22% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$20M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.66M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.5M |
| 2 |
ACM
AIHC Capital Management
Central,
|
-$13M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.6M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$4.88M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.79M |
AVBP Hedge Fund Activity: Q1 2026 in Review
139 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2026, worth a combined $969M — up 20% from $810M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AVBP positions and 17 closed out — a net gain of 19 holders — while 57 added to existing stakes and 28 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $20M. The largest seller was Fidelity Investments, cutting an estimated $15.5M.
- 139 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2026, up from 121 in Q4 2025.
- Funds reported $969M of ArriVent BioPharma stock for Q1 2026, up 20% quarter-over-quarter.
- 36 funds opened new ArriVent BioPharma positions in Q1 2026 and 17 closed out, a net change of +19 holders.
- The largest ArriVent BioPharma buyer in Q1 2026 was Vivo Capital, an estimated $20M added.
- The largest ArriVent BioPharma seller in Q1 2026 was Fidelity Investments, an estimated $15.5M sold.
Based on aggregated 13F filings for Q1 2026.